CPhI Annual Expert Industry Report: Part I

Amsterdam (ots/PRNewswire) -

Piramal Enterprises, Fujifilm Diosynth Biotechnologies and Vision
Consulting

Outline Market Predictions

ADCs, multiuse facilities and regulatory transparency and
integration seen

as the key drivers of tomorrow's healthcare targets

CPhI Worldwide [http://www.cphi.com ] and CPhI Pharma Evolution
[http://www.pharmaevolution.com ], part of UBM Live's Pharmaceutical
Portfolio, announce the release of the first section of its annual
report - with forward looking article submissions from Piramal
Enterprises, Fujifilm Diosynth Biotechnologies and Vision Consulting
- examining the global implications of regulatory failure, single use
technologies and the potential of antibody drug conjugates (ADC).

(Logo: http://photos.prnewswire.com/prnh/20130723/629764-a )

The outlook for the next few years is particularly optimistic for
the ADCs market where Piramal Enterprises Executive Director and COO
Vijay Shah envisages increased global investments and even the
arrival of a new blockbuster drug to treat solid tumours. However,
beyond the traditional cancer uses of ADCs he also forecasts this
class of therapeutics will provide indications such as inflammation -
demonstrating that ADCs are on the cusp of being the great
break-through that many analysts have predicted. Unsurprisingly, in
the short term the majority of ADCs will be for lymphoma treatment,
but IND (Investigational New Drug) submissions for this class of drug
will rise over 50% in the next five years - and ultimately the market
will grow to $10bn during the next 10 years. With such an increase in
the prevalence of new targets it's really only a matter of time
before we see ADCs providing therapeutic solutions to a range of
conditions and this market is likely to grow enormously over the next
five, 10 and even 20 years.

"In the past a major failing with ADCs has been that cytotoxic
agents were simply not active enough to kill the target cell with
such a small amount of payload - 0.01% - however, new technologies
that improve antibody and antigen conjugation could hold the key to
really unlocking their potential. Over the next 10 years we will see
ADCs with much higher penetration rates." - Vijay Shah

Fujifilm Diosynth Biotechnologies Senior Vice President of R&D and
Innovation, Mark Carver, warned however that unless we move towards a
"health based risk assessment" approach to single use technologies,
innovation could be compromised - particularly for promising targets
like ADCs that are often required to be manufactured in such
facilities. The problem for biologics is that single use facilities
are hugely increasing the costs of development and putting at risk
promising targets that are deemed unviable before their true
potential has been explored. With EMA guidelines likely to exacerbate
this trend, many innovative targets are likely to struggle to make it
into clinical trials.

The solution to this problem is health based approaches, so that
even when there is only partial data on early phase development work
and the likely doses they will be used at to support full PDE and
MACO (Maximum allowable carryover) values there is still sufficient
information to produce appropriate banding to evaluate risk. The cost
reductions and increase in innovation will help accelerate the
development of new biologics product classes and it's now up to the
regulators to implement these changes into the way assessments are
conducted that maintain safety without compromising innovation.

Similarly, Vision Consulting CEO Dilip Shah has collectively
examined the current regulatory environment and concludes that safety
and compliance can be both increased by regulators simplifying and
unifying their codes and working closer with industry. The problem,
however, is that over the last few years and into the foreseeable
future we are likely to see an increased number of deliberate
infringements (FDA warning letters), particularly as analytical
technologies increase. The resultant implication of these well
publicised large pharma infringements is that there is now a very
real threat that increasingly restrictive regulations will prevent
smaller, more innovative players entering the market. The answer,
Dilip Shah believes, will ultimately lie in producing a more
transparent process - and crucially one that is unified across the
globe - whereby regulators take a more active role in working
industry to evaluate procedures in a transparent and consultative
manner. However, for this new outcomes-based approach to be
successfully implemented, it would require global collaboration
amongst regulators, which is still something Dilip Shah does not
believe will happen for at least another five years.

CPhI and Pharma Evolution will release its remaining annual report
findings (10 further expert submissions) at CPhI 2013 , with a closed
session press conference on the reports taking place on the first day
of the event.

Agnes Shanley - Editor at CPhI Pharma Evolution - commenting on
the first part of the report's release: "This first part of the CPhI
Phama Evolution annual report, which has been produced with the help
of our global expert panel, clearly highlights the growth in
biologics and multiuse technologies that will help over the next five
years to re-invigorate a period of innovative medicines coming to
market- with much excitement and anticipation focussed on ADCs.
However, from what we have seen within these first report
submissions, it is clear that regulatory reform will be essential to
maintaining safety whilst creating an environment that is as flexible
as the marketplace to help induce increased innovation."

Chris Kilbee - Group Director, CPhI & Pharma, confirmed the
intention to distribute the full findings at this year's event: "At
CPhI we will be releasing the remaining 10 articles from our panel
members, which collectively will produce an in-depth overview of the
market and will enable the industry to take stock and look at the
implications over the next few years. We have designed these to be
open access and to increase discussion amongst the industry, so I
would encourage people to read the full submissions to get a fuller
picture of our experts' perspectives. I must also take this
opportunity to thank our panel for taking the time to provide their
perspectives within this report."

For full copies of the submissions and overall reports please
visit: http://downloads.deusm.com/pharmaevolution/CPhI-Annual-Industr
y-report-part-I.pdf

Report highlights

Antibody drug conjugates (ADC):

- Blockbuster drug for solid tumours predicted in next 10 years
- ADCs will come to market for indications beyond cancer, such as inflammation,
with a total market value of $10 billion by 2023
- Majority of ADCs for next five years will be for Lymphoma
- IND submissions expected to rise 50% over the next five years

Single- verses multi- use technologies:

- Within next five years it is projected that the industry will be forced to
move to 'health-based approach' to risk assessment in order to reduce costs
- Investigational medicinal products with limited data could start to be
produced in multiuse facilities
- EMA guidelines, if implemented fully, put innovation at risk by forcing
manufacturer in fully dedicated facilities - this could even prevent some
promising biologics target making it to clinical trial

Regulatory change:

- Tighter regulations as a result of large pharma infringements will prevent
smaller, more innovative companies entering the US market - reducing competitiveness
- More open transparent regulator could help facilitate improved standards
- A simpler global system must be found in order to improve regulatory
compliance, safety and innovation
- FDA warning letters predicted to rise over the next five years as analytical
technologies rise
- Large-scale integration of regulators unlikely despite the clear advantages
this would bring
- Deliberate infringements are on the rise

Notes to editors

About CPhI Pharma Evolution annual report and expert industry
panel

Earlier this year, CPhI launched a major new initiative with the
introduction of its annual report published in cooperation with
Pharma Evolution - written by a panel of world-leading experts across
the pharmaceutical supply chain.

The vision was to harness the power of CPhI's independent position
within the industry so that it could produce unbiased analysis of the
global pharmaceutical industry and help bring different perspectives
together.

The annual report utilises expert in-depth essays, looking at
future contingencies. Experts were given carte blanche to evaluate
current industry practices and examine the future implications for
the industry.

About CPhI

CPhI drives growth and innovation at every step of the global
pharmaceutical supply chain from drug discovery to finished dosage.
Through exhibitions, conferences and online communities, CPhI brings
together more than 100,000 pharmaceutical professionals each year to
network, identify business opportunities and expand the global
market. CPhI hosts events in Europe, China, India, Japan, Southeast
Asia, Russia and South America co-located with ICSE for contract
services, P-MEC for machinery, equipment & technology, InnoPack for
pharmaceutical packaging and BioPh for biopharma. CPhI provides an
online buyer & supplier directory at CPhI-Online.com and hosts a
global community with news and analysis at PharmaEvolution.com.

For more information visit: http://www.cphi.com

The UBM Live annual schedule of Pharmaceutical events also
includes CPhI Worldwide, ICSE, P-MEC Europe and InnoPack ; CPhI and
P-MEC India (3-5 December, 2013 at the Bombay Exhibition Centre in
Mumbai); CPhI, ICSE, P-MEC, BioPh and Pharmatec Japan ; CPhI Russia
and IPhEB (16-17 April, 2014 in St Petersburg, Russia); CPhI, P-MEC
and Innopack South East Asia (20-22 May, 2014 in Jakarta, Indonesia);
CPhI Istanbul (4-6 June, 2014, Turkey) and CPhI, Hi and Fi, ICSE,
P-MEC, BioPh and LabWorld China (26-28 June, 2014 at SNIEC, Shanghai,
China).

About CPhI Pharma Evolution

CPhI Pharma Evolution (http://www.pharmaevolution.com) launched in
February 2013 as a global online community where professionals from
across the pharmaceutical manufacturing sector can talk with their
peers and share best-practices and regulatory updates across the
pharmaceutical ingredient and contract manufacturing space. Pharma
Evolution is the new go-to community for industry professionals to
exchange thoughts and network on key areas including: formulation,
APIs, excipients, drug delivery, R&D, manufacturing and quality,
packaging and anti-counterfeiting, regulatory compliance, and
outsourcing and supply chain management. Pharma Evolution was created
as an extension of CPhI's global events business as a forum and
resource for pharmaceutical executives to employ 365 days a year.
Pharma Evolution is published by CPhI and UBM DeusM
(http://www.deusm.com), the marketing services division of UBM
specializing in building and operating highly engaged communities of
qualified users within specialist B2B markets, using a strategy of
best-practices focused on content and technology.

About UBM Live

UBM Live connects people and creates opportunities for companies
across five continents to develop new business, meet customers,
launch new products, promote their brands, and expand their market.
Through premier brands such as TFM&A, Internet World, IFSEC, MD&M,
CPhI, Cruise Shipping Miami, the Concrete Show, and many others, UBM
Live exhibitions, conferences, awards programs, publications,
websites, and training and certification programs are an integral
part of the marketing plans of companies across more than 20 industry
sectors.

For media enquiries, please contact:
Alex Heeley or Tristan Jervis
De Facto Communications
T: +44(0)207-203-6745 / 6740
E: a.heeley@defacto.com / t.jervis@defacto.com

Photo:
http://photos.prnewswire.com/prnh/20130723/629764-a

ots Originaltext: UBM Live
Im Internet recherchierbar: http://www.presseportal.de